Here’s a look at some of HHS Secretary Robert F. Kennedy Jr.'s claims about Americans' diets, vaccines, measles and autism, ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

It's probably safe to say that weight-loss drugs aren't going anywhere any time soon. According to the most recent data, six percent of American adults, or roughly 16 million people, take such ...

Pfizer said it would stop studying the pill after a participant in one of its trials experienced a drug-induced liver injury.

Advocates of obesity drugs have argued that covering the costly yet effective anti-obesity medications can reduce the government’s longer-term costs of future chronic illnesses associated with ...

The US Centers for Medicare & Medicaid Services (CMS) confirmed that it will not proceed with a Biden administration proposal to expand Medicare coverage for anti-obesity drugs such as Novo ...